Cargando…

Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report

Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74‐year‐old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durvalumab fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masuda, Kosuke, Nagai, Yoshiaki, Amari, Hikari, Tahara, Hiroki, Maeda, Yuki, Shiihara, Jun, Ohta, Hiromitsu, Hiruta, Masahiro, Yamaguchi, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626253/ https://www.ncbi.nlm.nih.gov/pubmed/37699791 http://dx.doi.org/10.1111/1759-7714.15104

Ejemplares similares

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
por: Shiihara, Jun, et al.
Publicado: (2021)

Steroid resistance in organizing pneumonia caused by pulmonary cryptococcosis
por: Nomura, Motoko, et al.
Publicado: (2020)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer
por: Inoue, Yoshiaki, et al.
Publicado: (2017)

Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab
por: Mizushina, Yoshiko, et al.
Publicado: (2021)

Immunoglobulin G4-related Pleuritis Complicated with Minimal Change Disease
por: Mizushina, Yoshiko, et al.
Publicado: (2021)

Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study
por: Li, Yuanming, et al.
Publicado: (2022)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series
por: Kanazu, Masaki, et al.
Publicado: (2018)

Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
por: Kawai, Shoko, et al.
Publicado: (2020)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
por: Ogasawara, Keita, et al.
Publicado: (2022)

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
por: Rocha, Pedro, et al.
Publicado: (2020)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
por: Yildirim, Hasan Cagri, et al.
Publicado: (2022)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Percutaneous consolidation of bone metastases: strategies and techniques
por: Cazzato, Roberto Luigi, et al.
Publicado: (2019)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer
por: Doki, Yuichiro, et al.
Publicado: (2022)

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
por: Liu, Yufei, et al.
Publicado: (2022)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
por: Kishi, Noriko, et al.
Publicado: (2022)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7t1h5j33ii8dppqnnnq06jcslp